LONDON, UK I September 24, 2024 I Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to announce that the European Medicines Agency (EMA) has granted approval to commence a clinical trial for its highly-selective PARP1 inhibitor, DSB2455. This potentially best-in-class, potent, highly selective and CNS-penetrant agent targets cancers that harbour homologous recombination deficiencies (HRD) including BRCA mutations. The safety profile of first generation non-selective PARP1/2 inhibitors has restricted their application, particularly in combination with chemotherapy and radiotherapy. By selectively inhibiting PARP1, we believe that DSB2455 has the potential to achieve a significantly enhanced therapeutic index, representing a significant advancement in precision medicine cancer treatment. Preliminary data indicate a strong safety profile and compelling efficacy in preclinical studies, paving the way to open our trial in the clinic.
Alan Wise, CEO of Duke Street Bio, commented, “The approval of the DSB2455 First-in-Human clinical trial by the EMA is a testament to the therapeutic potential of our innovative approach in the DDR space. Duke Street Bio’s mission is to improve patient outcomes and bring new hope to individuals battling cancer. We believe that DSB2455 has the potential for improved efficacy and tolerability versus first-generation PARP inhibitors in patient populations where there is still significant unmet medical need.”
For more information about Duke Street Bio and our upcoming clinical trial, please visit www.dukestbio.com
About Duke Street Bio:
Duke Street Bio is at the forefront of developing therapies that reprogram tumour biology by targeting the underlying genetic and immune pathways that fuel tumour growth. We are dedicated to improving the lives of patients facing a cancer diagnosis through groundbreaking research and innovative treatments.
SOURCE: Duke Street Bio
Post Views: 88
LONDON, UK I September 24, 2024 I Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to announce that the European Medicines Agency (EMA) has granted approval to commence a clinical trial for its highly-selective PARP1 inhibitor, DSB2455. This potentially best-in-class, potent, highly selective and CNS-penetrant agent targets cancers that harbour homologous recombination deficiencies (HRD) including BRCA mutations. The safety profile of first generation non-selective PARP1/2 inhibitors has restricted their application, particularly in combination with chemotherapy and radiotherapy. By selectively inhibiting PARP1, we believe that DSB2455 has the potential to achieve a significantly enhanced therapeutic index, representing a significant advancement in precision medicine cancer treatment. Preliminary data indicate a strong safety profile and compelling efficacy in preclinical studies, paving the way to open our trial in the clinic.
Alan Wise, CEO of Duke Street Bio, commented, “The approval of the DSB2455 First-in-Human clinical trial by the EMA is a testament to the therapeutic potential of our innovative approach in the DDR space. Duke Street Bio’s mission is to improve patient outcomes and bring new hope to individuals battling cancer. We believe that DSB2455 has the potential for improved efficacy and tolerability versus first-generation PARP inhibitors in patient populations where there is still significant unmet medical need.”
For more information about Duke Street Bio and our upcoming clinical trial, please visit www.dukestbio.com
About Duke Street Bio:
Duke Street Bio is at the forefront of developing therapies that reprogram tumour biology by targeting the underlying genetic and immune pathways that fuel tumour growth. We are dedicated to improving the lives of patients facing a cancer diagnosis through groundbreaking research and innovative treatments.
SOURCE: Duke Street Bio
Post Views: 88
